Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
76. |
ECCT/24/06/03 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Walter Otieno Site(s) in Kenya 1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county) |
View |
77. |
ECCT/24/02/06 | INAVO122 A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CAâ€mutated HER2â€positive locally advanced or metastatic breast cancer |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
78. |
ECCT/22/01/04 | SKYSCRAPER 07 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
79. |
ECCT/24/06/05 | SII-qHPV Vaccine Study A Phase-3b, partially double-blind, randomized, multi-country clinical study to evaluate the immunogenicity, safety, and reactogenicity of SIIPL qHPV vaccine (CERVAVAC®) in women living with HIV aged 15-25 years. |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya 1. KEMRI-CCR PHRD Thika (Kiambu county) 2. KEMRI - CCR Nairobi (Nairobi City county) |
View |
80. |
ECCT/15/12/05 | Post-discharge Malaria Chemoprevention(PMC) study Malaria Chemoprevention with monthly treatment with dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: A 3-year, multi-centre, parallel-group, two-arm randomised placebo controlled superiority trial |
Principal Investigator(s) 1. Titus Kwambai 2. Simon Kariuki Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Homa Bay County Referral Hospital (Homa Bay county) 3. Migori County Referral Hospital (Migori county) 4. Busia County Referral Hospital (Busia county) |
View |